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Abstract Recent studies have revealed in normal thyroid
tissue the presence of the transcript of several phosphodi-
esterases (PDEs), enzymes responsible for the hydrolysis of
cyclic nucleotides. In this work, we analyzed the expres-
sion of PDE5 in a series of human papillary thyroid car-
cinomas (PTCs) presenting or not BRAF V600E mutation
and classified according to ATA risk criteria. Furthermore,
we tested the effects of two PDE5 inhibitors (sildenafil,
tadalafil) against human thyroid cancer cells. PDE5 gene
and protein expression were analyzed in two different co-
horts of PTCs by real-time PCR using a TaqMan micro-
fluid card system and Western blot. MTT and migration
assay were used to evaluate the effects of PDE5 inhibitors
on proliferation and migration of TPC-1, BCPAP, and
8505C cells. In a first series of 36 PTCs, we found higher
expression levels of PDE5A in tumors versus non-tumor
(normal) tissues. PTCs with BRAF mutation showed higher
levels of mRNA compared with those without mutation.
No significant differences were detected between sub-
groups with low and intermediate ATA risk. Upregulation
of PDE5 was also detected in tumor tissue proteins. Similar
results were obtained analyzing the second cohort of 50
PTCs. Moreover, all tumor tissues with high PDE5 levels
showed reduction of Thyroglobulin, TSH receptor, Thy-
roperoxidase, and NIS transcripts. In thyroid cancer cells
in vitro, sildenafil and tadalafil determined a reduction of
proliferation and cellular migration. Our findings demon-
strate for the first time an overexpression of PDE5 in PTCs,
and the ability of PDE5 inhibitors to block the proliferation
of thyroid cancer cells in culture, therefore, suggesting that
specific inhibition of PDE5 may be proposed for the
treatment of these tumors.
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Introduction
An increase of thyroid carcinomas, and in particular the
papillary histotype, has been registered in the last decade
[1, 2]. Together with the well-differentiated forms, which
are efficaciously managed by the treatment with surgery
and radioiodine, an increased prevalence was reported also
for the less differentiated carcinomas [1, 3]. These tumors
are unable to concentrate this radioisotope and do not re-
spond to the standard treatment or develop radio resistance
[4, 5]. These unresponsive tumors are characterized by an
altered phenotype, often including the reduction/loss of
expression of sodium/iodide symporter (NIS) and thy-
roperoxidase (TPO), owing to the oncogenic activation of
intracellular signal transduction pathways which control
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cell growth and differentiation [6–9]. Study of the regula-
tion of intracellular messengers, therefore, may help to
identify molecular targets for novel therapeutic approaches.
Alterations of intracellular cyclic AMP (cAMP) levels
deriving by mutations in the TSH receptor (TSH-R) gene
have been extensively investigated, and it is well estab-
lished their pathogenic role in several thyroid diseases,
including hyperfuncting adenomas (gain-of-function mu-
tations) as well as forms of hypothyroidism (inactivating
TSHR mutations) [10–12]. Less defined is the role of
cGMP in thyroid cells [13, 14]. Intracellular levels of the
cyclic nucleotides are modulated by phosphodiesterases
(PDEs), enzymes able to hydrolyze both cAMP and cGMP,
and therefore acting as physiological regulators of all the
processes mediated by such second messengers [15].
Normal thyroid tissues express subtypes PDE4, PDE5,
PDE7, and PDE8 [16]. Moreover, expression of PDE4,
able to hydrolyze the cAMP, was also reported to play a
regulatory role in toxic adenomas carrying mutations in the
TSH-R gene [17]. In contrast, there are no data on the
expression of PDE5 (responsible for hydrolysis of cGMP)
in thyroid cancer cells.
In this study, we have analyzed the expression of PDE5
in surgical specimens of two series of human papillary
thyroid tumor tissues (n = 86, in total), measuring both
gene and, when available, protein expression levels, and
comparing its expression with those of some thyroid-
specific genes. The relationship with BRAF mutational
status and other biological features determining clinic-
pathologic features predicting the risk assessment (low or
intermediate category) of recurrence was also investigated.
To verify the possibility to target the PDE5 for therapeutic
purpose, we also tested the effects of two PDE5 inhibitors on
the growth and migration properties of three human thyroid
cell lines derived from papillary (TPC-1 and BCPAP cells)
and anaplastic thyroid carcinoma (8505C cells).
Materials and methods
Collection of thyroid tissues
Tumor thyroid tissues were collected from patients sub-
jected to thyroidectomy for PTC at the Sapienza’s
University Hospital of Rome, Policlinico Umberto I. Two
independent cohorts were studied. An exploratory cohort
(n = 36) was used for generating the hypothesis, a con-
firmatory cohort (n = 50) to test it. For each patient, a
sample of thyroid tumor tissue and, when available, also
contralateral normal tissue was collected, snap-frozen, and
stored in liquid nitrogen. All 86 cases were risk-stratified
(low or intermediate risk category) on the basis of clinical
and pathological features in accordance with the 2009
American Thyroid Association (ATA) initial risk stratifi-
cation system guidelines [18], and the presence or not of
somatic BRAF V600E mutation detected by direct se-
quencing was performed in cDNA samples of tumor tissues
as described previously [19]. All Patients’ tumors infor-
mation (exploratory and confirmatory cohorts combined)
are reported in Table 1. All human tissue samples used in
the study were collected with full Patients’ informed
written consent and approval from the Policlinico Umberto
I Ethical Committee of Rome.
Extraction of RNA and gene expression studies
Total RNA was isolated using TRIzol reagent (Life
Technologies, Foster City, CA, USA) following the
manufacturer’s recommended protocol and quantified with
a NanoDrop Spectrophotometer (Thermo Fisher Scientific,
Inc., Waltham, MA, USA). cDNAs were obtained follow-
ing the protocol provided with the High Capacity cDNA
Table 1 Characteristics of the study population at the time of pri-
mary surgery
Characteristic Study cohort (n = 86)
Sex (n, rate)
Male 28 (32.6)
Female 58 (67.4)
Age at diagnosis, years (median, range) 44.5 (18–81)
Histological variant (n, rate)
PTC-cl 72 (83.7)
PTC-fv 12 (14)
PTC-other 2 (2.3)
Tumor size, mm (median, range) 12 (3–38)
Tumor foci (n, rate)
Unifocal 69 (80.2)
Multifocal 17 (19.8)
Extrathyroidal extension (n, rate)
No 52 (60.5)
Minor 34 (39.5)
Lymph node metastases (n, rate)
No 56 (65.1)
Yes 30 (34.9)
ATA Risk (n, rate)a
Low 37 (43)
Intermediate 49 (57)
BRAF mutational status (n, rate)
wt 30 (34.8)
V600E 55 (64)
V600_K601delinsE 1 (1.2)
ATA American Thyroid Association, PTC-cl classical variant, PTC-fv
follicular variant, wt wild type
a 2009 American Thyroid Association risk stratification staging
system
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Reverse Transcription kit (Life Technologies). To evaluate
the expression of PDE5A, NIS, TPO, Thyroglobulin (Tg),
and TSH-R genes in thyroid normal and tumor tissues, real-
time PCR was performed using custom Taqman Low
Density Arrays (TLDA, Life Technologies). Specific pre-
designed assays were performed to configure each TLDA
(TaqMan Gene Expression Assays, Life Technologies)
through one replicate for biological sample. Four house-
keeping genes (Beta-actin, Glyceraldehyde-3-Phosphate
Dehydrogenase, Hypoxanthine Phosphoribosyltransferase
1, and Beta-2 microglobulin) were carried out to normalize
RNA expression levels [20]. CT values were calculated
through the SDS software (version 2.4) and used to cal-
culate relative quantification (RQ) with RQ Manager
software (Life Technologies). In detail, beta-actin was
chosen as endogenous control due to its lower variation
among samples, and final results were expressed as relative
expression normalized to a calibrator sample.
Protein extraction and western blot analysis
Extraction of total proteins was performed as previously
described [21]. 20 lg of proteins was run on a 9 or 12 %
SDS-PAGE gel, transferred to PVDF membrane (2 h at
225 mA) (VWR, Milan, Italy), blocked with TTBS/milk
(TBS, 1 % Tween 20 and 5 % non-fat dry milk) and in-
cubated overnight with affinity-purified anti-PDE5 (Santa
Cruz, Milan, Italy), diluted 1:500 for tissues and 1:100 for
cells and anti-b-actin antibodies (Sigma Aldrich, Segrate,
Milan, Italy) (used as internal control) diluted 1:10,000.
The membranes were washed in TTBS and incubated with
horseradish peroxidase-conjugated anti-rabbit or anti-
mouse antibody (Transduction Laboratories, Lexington,
KY, USA) diluted 1:10,000 or 1:20,000 in TTBS/milk. The
protein was visualized by chemiluminescence using the
Western blot detection system ECL (VWR) and Western
lightning Plus-ECL (Perkin Elmer, Milan, Italy). Quan-
tification was achieved by densitometric scanning.
Thyroid cancer cell lines
For in vitro experiment, we used human papillary (BCPAP
and TPC-1, provided by Prof. A. Fusco) and anaplastic
(8505C provided by Dr. C. Nucera) thyroid carcinoma cell
lines, confirmed as of thyroid cancer origin and hosting the
RET-PTC (TPC-1) or BRAF (BCPAP and 8505C) geno-
typic alteration, respectively [22]. The cells were cultured
as previously described [23, 24].
MTT assay
TPC-1, BCPAP, and 8505C cells were seeded in 96-well
plates at a density of 3 9 103 (TPC-1 and 8505C) or
5 9 103 (BCPAP). Proliferation was assessed by MTT
[25]. After 24 h, growth medium was replaced by fresh
normal medium supplemented with sildenafil and tadalafil
(Aurogene, Roma, Italy) (1, 10, 100 lM), and cells were
incubated for 24 and 48 h. Then, the solubilized product
was quantified with a microplate spectrophotometer
(Multiskan MS 6.0, Labsystems) at a wavelength of
540 nm and a reference wavelength of 690 nm. Results are
expressed as percentages over untreated cultures (control).
Migration assay
Cell migration assay was performed using Transwell in-
serts with 8 lm pore (Constar; Euroclone, Milan, Italy), as
previously described [26]. Briefly, cells were treated with
sildenafil (0.01, 0.1, 1, and 10 lM) and tadalafil (0.01, 0.1,
1, and 10 lM) for 24 h, trypsinized, and centrifuged
(1200 rpm for 5 min). After suspension in medium without
serum, the pellet was centrifuged (1200 rpm for 5 min) and
suspended in medium containing 1 % BSA. Then, the cells
were plated in the upper chamber of filters at a density of
50 9 103 cells (in 100 lL) while in the inferior chamber
were added 600 lL of medium containing 10 % FBS.
After 6 h of incubation, cells not migrated were removed
from the upper surface of the filters with cotton swabs,
while the filters were fixed and stained with Diff-Quick.
Migrated cells were counted in five random fields using an
eyepiece equipped with a counting grid.
Statistical analysis
The results are expressed as mean ± standard deviation
(SD). For cell proliferation and cell migration assay was
adopted the one-way ANOVA followed by the Tukey–
Kramer multiple comparisons test using GraphPad Prism
version 5.0 statistical software (GraphPad Software Inc.,
San Diego, CA, USA). Analysis of mRNA levels was
performed by Mann–Whitney test. p values lower than 0.05
were considered statistically significant.
Results
Gene and protein expression of PDE5 and clinical-
pathological features of PTCs
We first examined by TLDA the expression of PDE5A in a
series of 36 tissues from patients with sporadic PTC (ex-
ploratory cohort). These tumors, according to ATA risk
classification system, included 17 with a low degree of risk
and 19 with intermediate risk. Among them, 7 and 14 carry
the BRAF V600E mutation, respectively (Table 1).
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Expression levels of PDE5A resulted significantly
higher in the tumor tissues compared to a pool of non-
tumor (normal) tissues and also in BRAF V600E, when
compared with BRAF wild-type PTCs (p \ 0.0001 and
p \ 0.01, respectively). No differences were observed be-
tween low risk and intermediate risk PTCs (Fig. 1a). This
analysis was replicated in a wider and independent cohort
of patients with sporadic PTCs (n = 50), and results were
confirmed (Fig. 1b).
Data of PDE5A transcript levels were then compared
with those of the thyroid-specific genes NIS, TPO, Tg, and
TSH-R. As shown in Fig. 2, while almost all tumor samples
had higher PDE5A expression levels as compared to nor-
mal samples, they displayed significantly lower mRNA
levels of thyroid-specific genes (Fig. 2).
Subsequently, Western blot analysis performed in pro-
tein extracts of a series of PTCs showed higher level of
protein expression in tumor tissues compared to normal
counterpart (Fig. 3), confirming the finding obtained with
mRNA analysis.
Effects of sildenafil and tadalafil on proliferation
and migration of thyroid cancer cells
To evaluate the effects of PDE5 inhibition on thyroid tu-
mor cells, we examined viability and migration properties
of BCPAP, TPC-1 (from PTC), and 8505C (from ATC)
cells incubated with sildenafil and tadalafil, two different
specific inhibitors of PDE5. All cell lines showed de-
tectable levels of PDE5 (Fig. 4). As shown in Fig. 5,
treatment with 1, 10, 100 lM of sildenafil or tadalafil for
24 and 48 h reduced the proliferation of all three cell lines
with similar trend. In particular, the strongest inhibiting
effect (about 50 % vs. control) was observed using the
100 lM concentration of tadalafil in all cell lines
(p \ 0.05, p \ 0.01, p \ 0.001 vs. control). At the same
concentration, minor but significant effect was exerted by
sildenafil on BCPAP and 8505C cells after 48 h (p \ 0.05,
p \ 0.01 vs. control).
Next, effects of PDE5 inhibitors on cell migration were
evaluated. As shown in Fig. 6, in BCPAP and 8505C cell
lines, a reduction of the migration was observed at 0.1, 1,
and 10 lM (8505C and BCPAP cells *50 % vs. untreated
cells; p \ 0.001 and 0.05, respectively).
Interestingly and in accordance with our previous
in vivo data on BRAF mutated tumors, the cells carrying
the BRAF V600E mutation (8505C and BCPAP) showed a
better response to PDE5 inhibition in both anti-prolif-
erative and anti-migration action of both inhibitors.
Discussion
Novel approaches are currently under investigation for the
management of those differentiated thyroid cancers re-
fractory to radioiodine therapy. A major alteration detected
in such thyroid cancer cells regards the machinery re-
sponsible for iodide uptake and concentration, primary
involving the sodium/iodide symporter, caused by genetic
and epigenetic abnormalities especially detected in
metastatic lesions [27–31]. Almost all the known genetic
alterations occur in elements of signal transduction path-
ways controlling both cell growth and differentiation. In
PTCs, activating BRAF mutation represents the most fre-
quent genetic alteration and is also considered as a marker
of aggressiveness [32–35].
Fig. 1 mRNA levels of PDE5A
in PTCs. Expression levels of
PDE5A in two series of thyroid
tumor tissues [exploratory
group, n = 36 (a); confirmatory
group, n = 50 (b)] compared to
pool of normal tissues. In both
series, analysis of subgroups
(PTCs with BRAF V600E vs.
BRAF wild type, and PTC
classified as intermediate ATA
risk vs. low risk) is reported.
Data represent the mean ± SD.
p value was obtained by Mann–
Whitney test. *p \ 0.01,
***p \ 0.0001, ns not
significant
Endocrine
123
At variance with cAMP and its pathway, widely inves-
tigated as the main mediator of the TSH effects on thyroid
cells and involved in several thyroid diseases [10], the role
of the regulation of cGMP, mainly exerted by PDEs, in
thyroid cancer has never been investigated. PDEs may be
considered a key therapeutic target, and quantitative RT-
PCR analysis has revealed the mRNA expression profile of
all PDE isoenzymes in human brain and peripheral tissues
and in normal thyroid gland, which expressed the tran-
scripts of PDE4, PDE7, PDE8, and PDE5 [16]. The latter
enzyme acts specifically hydrolyzing the cGMP and is
encoded by one gene, PDE5A, with three variants:
PDE5A1 (*100 kDa), PDE5A2 (*95 kDa), and PDE5A3
(*95 kDa) [36].
Our results show for the first time an increased expres-
sion of PDE5, both at mRNA and protein levels, in a total
of 86 PTCs belonging to two independent cohorts. In-
creased transcript of PDE5A was also associated with de-
crease of the transcript of some differentiation markers as
Fig. 2 PDE5 and thyroid-
specific genes mRNA levels in
PTCs. mRNA levels of PDE5A
(a), NIS (b), Tg (c), TPO (d),
and TSH-R (e), measured by
real-time RT-PCR, are reported
for each tumor. Results are
expressed as fold of increase/
decrease (RQ ± SD) relative to
mean of normal thyroid tissues,
considered arbitrarily as 1. RQ
relative quantification, SD
standard deviation
Fig. 3 Expression of PDE5 protein in PTCs. A couple of bands of
approximately 95 and 100 kDa, corresponding to human PDE5
protein, was detected by Western blot analysis in the total protein
extracts of normal (N) and tumor (T) tissues, with BRAF wild type or
carrying the V600E mutation. Data shown are relative to a
representative group of samples
Fig. 4 PDE5 espression in thyroid cancer cells. PDE5 was detectable
in BCPAP, TPC-1, and 8505C cells. Western blot analysis represen-
tative of three different experiments (a). Values were obtained from
densitometric scanning bands from Western blot; the amounts of b-
actin were evaluated for normalization (b)
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TSH-R, Tg, TPO, and NIS, all implicated in intra-thyroidal
iodine metabolism and thyroid hormone synthesis. More-
over, by analyzing the clinicobiological chart of the pa-
tients, we noted presence of higher expression levels of
PDE in PTCs with BRAF V600E mutation. However, in-
crease of PDE5A mRNA levels cannot be associated with
the aggressiveness of the tumors, since no differences were
observed comparing the subgroups classified according to
the 2009 ATA criteria risk stratification system as low and
intermediate risk. Interestingly, in a parallel study focusing
on genome abnormality, amplification of PDE5A gene re-
sulted a frequent lesion detected in PTCs, independent
from their aggressiveness (unpublished observation).
The present findings prompted us to test the effects of
PDE5 inhibition in thyroid cancer cells. We considered as
bona fide results those determined in a concordant way by
two different PDE5 inhibitors, sildenafil and tadalafil,
currently approved for use in male erectile dysfunction and
in pulmonary hypertension [37–40]. Moreover, there is
considerable excitement regarding the potential use of
PDE5 inhibitors as therapeutics for cardiovascular dis-
eases, including hypertension, ischaemic cardiomyopathy,
cardiac failure, stroke, peripheral myopathy, and cardiac
dysfunction in Duchenne muscular dystrophy, as well as
insulin resistance, type 2 diabetes, and metabolic syn-
drome, and several clinical trials are in progress [41].
Various PDE1 to PDE5 selective inhibitors have also been
reported to inhibit growth and induce apoptosis in many
different cancer cell lines, suggesting a potential role for
this family of drugs also as antineoplastic agents [41].
We found a significant inhibitory action of both mole-
cules on the growth of three human cancer cell lines. At
lower doses, sildenafil and tadalafil were also able to re-
duce the capacity of the tumor cells to migrate, a funda-
mental step for the metastatic spread of the neoplastic
disease. Also, the effects of sildenafil and tadalafil were
stronger in the cell lines (BCPAP and 8505C) carrying the
BRAF mutation. Together with our in vivo results, higher
Fig. 5 Effects of sildenafil and tadalafil on cell viability. MTT assay
was performed to analyze the effects of sildenafil and tadalafil at 1,
10, and 100 lM after 24 and 48 h incubation on TPC-1, BCPAP, and
8505C cells. Results are expressed as mean ± SD from at least three
independent experiments performed in eigthplicate. *p \ 0.05 vs.
control; **p \ 0.01; ***p \ 0.001 vs. control
Fig. 6 Effect of sildenafil and tadalafil on cell migration. Migration
through gelatine coated filters was analyzed after treatment with
sildenafil or tadalafil for 24 h. Results are mean ± SD of three
independent experiments, and statistical analysis was performed using
the Tukey–Kramer multiple comparisons test. *p \ 0.05 vs. control;
**p \ 0.01 vs. control; ***p \ 0.001 vs. control
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expression of PDE5 in BRAF mutated tumors, this finding
would suggest that these PTCs could represent a prefer-
ential target for the action of PDE5 inhibitors.
In conclusion, our finding demonstrate for the first time
an overexpression of PDE5 in PTCs and the ability of
PDE5 inhibitors to block the proliferation of thyroid cancer
cells in culture. Further studies in experimental models
in vivo will clarify whether specific inhibition of PDE5
may be proposed for the treatment of these tumors.
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